{"result":[{"lastName":"Kurian","clinicalFocus":[{"focus":"Cancer Genetics"},{"focus":"Medical Oncology"},{"focus":"Breast Cancer Risk"}],"appointments":[{"appointment":"Assistant Professor - Med Center Line,Medicine - Oncology"},{"appointment":"Assistant Professor - Med Center Line,Health Research & Policy"},{"appointment":"Member,Cancer Center"}],"primaryAppointment":"Assistant Professor - Med Center Line,Medicine - Oncology","imageUrl":"http://med.stanford.edu/profiles/viewImage?facultyId=6431&type=small&showNoImage","displayName":"Allison W. Kurian, M.D., M.Sc.","firstName":"Allison","href":"http://med.stanford.edu/profiles/cancer/researcher/Allison_Kurian","researchInterest":"Breast and gynecologic cancer epidemiology, risk assessment, and risk reduction."},{"lastName":"Fisher","clinicalFocus":[],"appointments":[{"appointment":"Associate Professor - Med Center Line,Medicine - Oncology"},{"appointment":"Member,Cancer Center"}],"primaryAppointment":"Associate Professor - Med Center Line,Medicine - Oncology","imageUrl":"http://med.stanford.edu/profiles/viewImage?facultyId=4644&type=small&showNoImage","displayName":"George A. Fisher Jr.","firstName":"George","href":"http://med.stanford.edu/profiles/cancer/researcher/George_Fisher","researchInterest":"Clinical expertise in GI cancers with research which emphasizes Phase I and II clinical trials of novel therapies but also includes translational studies including biomarkers, molecular imaging, tumor immunology and development of immunotherapeutic trials."},{"lastName":"Sikic","clinicalFocus":[{"focus":"Medical Oncology"},{"focus":"New Drug Studies"}],"appointments":[{"appointment":"Professor,Medicine - Oncology"},{"appointment":"Member,Cancer Center"}],"primaryAppointment":"Professor,Medicine - Oncology","imageUrl":"http://med.stanford.edu/profiles/viewImage?facultyId=4131&type=small&showNoImage","displayName":"Branimir I. Sikic, M. D.","firstName":"Branimir","href":"http://med.stanford.edu/profiles/cancer/researcher/Branimir_Sikic","researchInterest":"Research Interests: cancer pharmacology, mechanisms of resistance to anticancer drugs, regulation and function of MDR1 and tubulin genes, clinical trials of modulation of drug resistance, general oncology, Phase I trials of new drugs, gene expression profiling of cancers"},{"lastName":"Alli","clinicalFocus":[],"appointments":[{"appointment":"Postdoctoral Research fellow, School of Medicine"}],"primaryAppointment":"Postdoctoral Research fellow, School of Medicine","imageUrl":"http://med.stanford.edu/profiles/viewImage?facultyId=9711&type=small&showNoImage","displayName":"Elizabeth Alli","firstName":"Elizabeth","href":"http://med.stanford.edu/profiles/cancer/researcher/Elizabeth_Alli","researchInterest":"I am interested in identifying targeted therapies for triple-negative breast cancers and developing a novel strategy of biomarker-based chemoprevention for hereditary cancers that arise due to mutations in the Breast Cancer Susceptibility Gene 1 (BRCA1)."},{"lastName":"Oberhelman","clinicalFocus":[{"focus":"General Surgery"}],"appointments":[{"appointment":"Emeritus (Active) Professor,Surgery - General Surgery"},{"appointment":"Emeritus Faculty, Acad Council,Surgery - General Surgery"}],"primaryAppointment":"Emeritus (Active) Professor,Surgery - General Surgery","imageUrl":"http://med.stanford.edu/profiles/viewImage?facultyId=4526&type=small&showNoImage","displayName":"Harry A. Oberhelman","firstName":"Harry","href":"http://med.stanford.edu/profiles/cancer/researcher/Harry_Oberhelman","researchInterest":""},{"lastName":"Hanawalt","clinicalFocus":[],"appointments":[{"appointment":"Professor,Biology (School of Humanities and Sciences)"},{"appointment":"Professor,Dermatology"},{"appointment":"Member,Bio-X"},{"appointment":"Member,Cancer Center"}],"primaryAppointment":"Professor,Biology (School of Humanities and Sciences)","imageUrl":"http://med.stanford.edu/profiles/viewImage?facultyId=5957&type=small&showNoImage","displayName":"Philip Hanawalt","firstName":"Philip","href":"http://med.stanford.edu/profiles/cancer/researcher/Philip_Hanawalt","researchInterest":"Hanawalt has been a productive researcher in the field of DNA repair since his pioneering discovery of repair replication in E. coli in 1963. He also first demonstrated repair replication in mycoplasmata and in a eukaryote and he has developed a number of important experimental approaches for studying repair, beginning with the BrdUrd density labeling method for resolving semiconservatively replicated DNA from parental DNA containing repair patches. Hanawalt\u0092s approach was used to validate the "},{"lastName":"Chu","clinicalFocus":[{"focus":"Oncology"}],"appointments":[{"appointment":"Professor,Medicine - Oncology"},{"appointment":"Professor,Biochemistry"},{"appointment":"Member,Bio-X"},{"appointment":"Member,Cancer Center"}],"primaryAppointment":"Professor,Medicine - Oncology","imageUrl":"http://med.stanford.edu/profiles/viewImage?facultyId=4149&type=small&showNoImage","displayName":"Gilbert Chu","firstName":"Gilbert","href":"http://med.stanford.edu/profiles/cancer/researcher/Gilbert_Chu","researchInterest":"Our laboratory focuses on understanding how cells respond to DNA damage. Our research currently involves areas that interact with each other: repair of radiation damage, and transcriptional responses to DNA damage."},{"lastName":"Whittemore","clinicalFocus":[],"appointments":[{"appointment":"Professor,Health Research & Policy - Epidemiology"},{"appointment":"Member,Cancer Center"}],"primaryAppointment":"Professor,Health Research & Policy - Epidemiology","imageUrl":"http://med.stanford.edu/profiles/viewImage?facultyId=4482&type=small&showNoImage","displayName":"Alice S Whittemore","firstName":"Alice","href":"http://med.stanford.edu/profiles/cancer/researcher/Alice_Whittemore","researchInterest":"Cancers of the prostate, breast and ovary account for a major proportion of new cancer cases and cancer deaths in the U.S. each year. Our recent research focus has been on developing improved statistical methods for the design and conduct of studies involving hereditary predisposition and modifiable lifestyle characteristics in the etiologies of site-specific cancers."},{"lastName":"Longacre","clinicalFocus":[{"focus":"Anatomic/Clinical Pathology"},{"focus":"Pathology and Laboratory Medicine"}],"appointments":[{"appointment":"Professor - Med Center Line,Pathology"},{"appointment":"Member,Cancer Center"}],"primaryAppointment":"Professor - Med Center Line,Pathology","imageUrl":"http://med.stanford.edu/profiles/viewImage?facultyId=6082&type=small&showNoImage","displayName":"Teri A Longacre","firstName":"Teri","href":"http://med.stanford.edu/profiles/cancer/researcher/Teri_Longacre","researchInterest":"Gynecological, breast and gastrointestinal pathology with major emphasis on ovarian cancer and ovarian tumors of low malignant potential. Pathology of familial and hereditary breast-ovarian-GI cancer."},{"lastName":"Cimprich","clinicalFocus":[],"appointments":[{"appointment":"Associate Professor,Chemical and Systems Biology"},{"appointment":"Associate Professor (By courtesy),Chemistry"},{"appointment":"Member,Bio-X"},{"appointment":"Member,Cancer Center"}],"primaryAppointment":"Associate Professor,Chemical and Systems Biology","imageUrl":"http://med.stanford.edu/profiles/viewImage?facultyId=4417&type=small&showNoImage","displayName":"Karlene Cimprich","firstName":"Karlene","href":"http://med.stanford.edu/profiles/cancer/researcher/Karlene_Cimprich","researchInterest":"The use of genetic, biochemical and chemical approaches to understand the DNA damage-induced cell cycle checkpoints and the processes that contribute to maintenance of genomic stability."},{"lastName":"Carlson","clinicalFocus":[{"focus":"Breast Cancer - Medical Oncology"},{"focus":"Oncology (Cancer)"},{"focus":"Medical Oncology"}],"appointments":[{"appointment":"Professor - Med Center Line,Medicine - Oncology"},{"appointment":"Member,Cancer Center"}],"primaryAppointment":"Professor - Med Center Line,Medicine - Oncology","imageUrl":"http://med.stanford.edu/profiles/viewImage?facultyId=4629&type=small&showNoImage","displayName":"Robert Carlson","firstName":"Robert","href":"http://med.stanford.edu/profiles/cancer/researcher/Robert_Carlson","researchInterest":"Clinical investigations in breast cancer include institutional and NSABP studies of chemoprevention, adjuvant therapy, psychosocial interventions, treatment of metastatic disease, methods of decreasing anthracycline cardiotoxicity, and modulation of multidrug resistance. Research in meta-analysis includes the performance of meta-analysis in a wide variety of settings in cancer treatment by the international Meta-Analysis Group in Cancer."},{"lastName":"Van Dam","clinicalFocus":[{"focus":"Gastroenterology"}],"appointments":[{"appointment":"Professor - Med Center Line,Medicine - Gastroenterology & Hepatology"},{"appointment":"Member,Bio-X"}],"primaryAppointment":"Professor - Med Center Line,Medicine - Gastroenterology & Hepatology","imageUrl":"http://med.stanford.edu/profiles/viewImage?facultyId=4349&type=small&showNoImage","displayName":"Jacques Van Dam, M.D., Ph.D.","firstName":"Jacques","href":"http://med.stanford.edu/profiles/cancer/researcher/Jacques_Van Dam","researchInterest":"Dr. Van Dam's research focus involves the use of Raman and light-scattering spectroscopy for the early detection and screening of gastrointestinal cancer."},{"lastName":"Plevritis","clinicalFocus":[],"appointments":[{"appointment":"Associate Professor (Research),Radiology - Diagnostic Radiology"},{"appointment":"Member,Bio-X"},{"appointment":"Member,Cancer Center"}],"primaryAppointment":"Associate Professor (Research),Radiology - Diagnostic Radiology","imageUrl":"http://med.stanford.edu/profiles/viewImage?facultyId=4724&type=small&showNoImage","displayName":"Sylvia K. Plevritis, PhD","firstName":"Sylvia","href":"http://med.stanford.edu/profiles/cancer/researcher/Sylvia_Plevritis","researchInterest":"My research program focuses on computational modeling of cancer biology and cancer outcomes. We develop stochastic models of the natural history of cancer based on clinical research data.   We estimate population-level outcomes under differing screening and treatment interventions.  We also analyze genomic and proteomic cancer data in order to identify molecular networks that are perturbed in cancer initiation and progression and relate these perturbations to patient outcomes."},{"lastName":"Giaccia","clinicalFocus":[],"appointments":[{"appointment":"Professor,Radiation Oncology - Radiation Biology"},{"appointment":"Professor (By courtesy),Obstetrics & Gynecology"},{"appointment":"Professor (By courtesy),Surgery"},{"appointment":"Member,Cancer Center"}],"primaryAppointment":"Professor,Radiation Oncology - Radiation Biology","imageUrl":"http://med.stanford.edu/profiles/viewImage?facultyId=4141&type=small&showNoImage","displayName":"Amato Giaccia","firstName":"Amato","href":"http://med.stanford.edu/profiles/cancer/researcher/Amato_Giaccia","researchInterest":"Cellular response to hypoxia and ionizing radiation; cell-cycle control, apoptosis and angiogenesis in transformed cells."},{"lastName":"Koong","clinicalFocus":[{"focus":"Colorectal Cancer"},{"focus":"Colorectal Cancer - Radiation Oncology"},{"focus":"Esophageal Cancer"},{"focus":"Esophageal Cancer - Radiation Oncology"},{"focus":"Liver Cancer"},{"focus":"Liver Cancer - Radiation Oncology"},{"focus":"Pancreatic Cancer "},{"focus":"Pancreatic Cancer - Radiation Oncology"},{"focus":"Radiation Oncology"},{"focus":"Rectal Cancer "},{"focus":"Rectal Cancer - Radiation Oncology"},{"focus":"Stomach Cancer "},{"focus":"Stomach Cancer - Radiation Oncology"}],"appointments":[{"appointment":"Assistant Professor,Radiation Oncology - Radiation Therapy"},{"appointment":"Member,Bio-X"},{"appointment":"Member,Cancer Center"}],"primaryAppointment":"Assistant Professor,Radiation Oncology - Radiation Therapy","imageUrl":"http://med.stanford.edu/profiles/viewImage?facultyId=4729&type=small&showNoImage","displayName":"Albert Koong","firstName":"Albert","href":"http://med.stanford.edu/profiles/cancer/researcher/Albert_Koong","researchInterest":"The focus of my laboratory is to understand the role of hypoxia and the tumor microenvironment on malignant progression. My clinical area of interest is in the application of chemoradiotherapy and stereotactic radiosurgery for GI maligancies"},{"lastName":"Dirbas","clinicalFocus":[{"focus":"Breast Cancer"},{"focus":"Breast Cancer - Surgery"},{"focus":"Breast Surgery"},{"focus":"General Surgery"},{"focus":"Surgical Oncology"},{"focus":"Breast-Conserving Surgery"},{"focus":"Breast Neoplasms"},{"focus":"Carcinoma, Ductal, Breast"},{"focus":"Paget's Disease of Breast"},{"focus":"Radiation Oncology"}],"appointments":[{"appointment":"Associate Professor - Med Center Line,Surgery - General Surgery"},{"appointment":"Member,Cancer Center"}],"primaryAppointment":"Associate Professor - Med Center Line,Surgery - General Surgery","imageUrl":"http://med.stanford.edu/profiles/viewImage?facultyId=4667&type=small&showNoImage","displayName":"Frederick M. Dirbas","firstName":"Frederick","href":"http://med.stanford.edu/profiles/cancer/researcher/Frederick_Dirbas","researchInterest":"My research interests are focused on minimizing the impact of breast cancer from a diagnostic and therapuetic standpoint. Breast MRI is a powerful tool to facilitate the screening for and staging of breast cancer, and can be valuable adjunct to guide breast surgery. Oncoplastic surgical techniques optimize cosmesis after breast cancer surgery. Accelerated radiotherapy after lumpectomy decreases radiotherapy treatment times from 6 weeks to just 1 to 5 days."},{"lastName":"Sage","clinicalFocus":[],"appointments":[{"appointment":"Assistant Professor,Pediatrics - Cancer Biology"},{"appointment":"Assistant Professor,Genetics"},{"appointment":"Member,Bio-X"},{"appointment":"Member,Cancer Center"}],"primaryAppointment":"Assistant Professor,Pediatrics - Cancer Biology","imageUrl":"http://med.stanford.edu/profiles/viewImage?facultyId=6009&type=small&showNoImage","displayName":"Julien Sage","firstName":"Julien","href":"http://med.stanford.edu/profiles/cancer/researcher/Julien_Sage","researchInterest":"Our goal is to define the molecular basis of cancer initiation and progression, focusing on the RB (retinoblastoma) tumor suppressor gene family. In particular, we investigate how RB and its family members p107 and p130 control embryonic and adult stem cells to ensure normal development and prevent cancer."},{"lastName":"John","clinicalFocus":[],"appointments":[{"appointment":"Member,Cancer Center"}],"primaryAppointment":"Member,Cancer Center","imageUrl":"http://med.stanford.edu/profiles/viewImage?facultyId=7425&type=small&showNoImage","displayName":"Esther M. John","firstName":"Esther","href":"http://med.stanford.edu/profiles/cancer/researcher/Esther_John","researchInterest":"Etiology of breast, prostate and ovarian cancer; cancer in Hispanics and African-Americans; migration and acculturation in Hispanics; modifiable lifestyle factors (vitamin D, physical activity, body size, heterocyclic amines, occupational exposures); genetic susceptibility; gene-environment interactions"},{"lastName":"Brown","clinicalFocus":[],"appointments":[{"appointment":"Professor,Radiation Oncology - Radiation Biology"},{"appointment":"Member,Cancer Center"}],"primaryAppointment":"Professor,Radiation Oncology - Radiation Biology","imageUrl":"http://med.stanford.edu/profiles/viewImage?facultyId=4536&type=small&showNoImage","displayName":"Martin Brown","firstName":"Martin","href":"http://med.stanford.edu/profiles/cancer/researcher/Martin_Brown","researchInterest":"We seek to understand the mechanisms responsible for the resistance of cancers to treatment and to develop strategies to overcome these resistances. We are using molecular and cellular techniques and mouse models to exploit tumor hypoxia with drugs activated by hypoxia and anaerobic bacteria as tumor-specific gene therapy vectors. We are also testing ways of inhibiting the bone marrow rescue of the tumor vasculature following therapy."},{"lastName":"Tang","clinicalFocus":[{"focus":"Dermatology"},{"focus":"Skin Cancer"},{"focus":"Epidemiology"},{"focus":"Clinical Trial"}],"appointments":[{"appointment":"Assistant Professor - Med Center Line,Dermatology"},{"appointment":"Member,Cancer Center"}],"primaryAppointment":"Assistant Professor - Med Center Line,Dermatology","imageUrl":"http://med.stanford.edu/profiles/viewImage?facultyId=10735&type=small&showNoImage","displayName":"Jean Y. Tang MD PhD","firstName":"Jean","href":"http://med.stanford.edu/profiles/cancer/researcher/Jean_Tang","researchInterest":"My research focuses on finding new ways to treat and prevent non-melanoma skin cancer. I am committed to bringing laboratory-based insights to benefit our patients. I am interested in these questions:\r\n1. How do we prevent skin cancer? \r\n2. What is the relationship between sunlight, vitamin D, and skin cancer risk? \r\n3. Can we target certain tumor signaling pathways (Hedgehog pathway) to treat basal cell carcinomas - the most common cancer in the US?"},{"lastName":"Jeffrey","clinicalFocus":[{"focus":"Surgical Oncology"},{"focus":"Breast Surgery"},{"focus":"General Surgery"}],"appointments":[{"appointment":"Associate Professor - Med Center Line,Surgery - General Surgery"},{"appointment":"Member,Bio-X"},{"appointment":"Member,Cancer Center"}],"primaryAppointment":"Associate Professor - Med Center Line,Surgery - General Surgery","imageUrl":"http://med.stanford.edu/profiles/viewImage?facultyId=4147&type=small&showNoImage","displayName":"Stefanie Jeffrey","firstName":"Stefanie","href":"http://med.stanford.edu/profiles/cancer/researcher/Stefanie_Jeffrey","researchInterest":"Lab research: development of robot to isolate live circulating tumor cells (CTCs); characterization of live CTCs and their role in metastatic process; breast cancer genomics using DNA microarrays; refinement of RNA amplification techniques; co-developer of NASA Smart Probe for in-vivo breast tumor analysis"},{"lastName":"King","clinicalFocus":[],"appointments":[{"appointment":"Instructor,Radiology - Diagnostic Radiology"}],"primaryAppointment":"Instructor,Radiology - Diagnostic Radiology","imageUrl":"http://med.stanford.edu/profiles/viewImage?facultyId=10623&type=small&showNoImage","displayName":"Bonnie King, PhD","firstName":"Bonnie","href":"http://med.stanford.edu/profiles/cancer/researcher/Bonnie_King","researchInterest":""},{"lastName":"Norton","clinicalFocus":[{"focus":"Adrenal Cancer"},{"focus":"Carcinoid Tumors"},{"focus":"Carcinoid Tumors - Endocrinology"},{"focus":"Carcinoid Tumors - Surgery "},{"focus":"Endocrine - Surgery"},{"focus":"Endocrinology Surgery"},{"focus":"Esophageal Cancer"},{"focus":"Esophageal Cancer - Thoracic Surgery"},{"focus":"Gastrointestinal Cancers"},{"focus":"Gastrointestinal Cancers - Surgical Oncology"},{"focus":"Gastrointestinal Oncology Surgery"},{"focus":"General Surgery"},{"focus":"Liver Cancer"},{"focus":"Liver Cancer - Surgery"},{"focus":"Multiple Endocrine Neoplasias"},{"focus":"Multiple Endocrine Neoplasias - Surgery"},{"focus":"Osteosarcoma "},{"focus":"Osteosarcoma - Surgery"},{"focus":"Pancreas Surgery"},{"focus":"Pancreatic Cancer "},{"focus":"Pancreatic Cancer - Surgery"},{"focus":"Parathyroid Disease"},{"focus":"Parathyroid Disease - Surgery"},{"focus":"Sarcomas - Soft Tissue "},{"focus":"Sarcomas - Soft Tissue - Surgery"},{"focus":"Sarcomas - Surgical Oncology"},{"focus":"Stomach Cancer "},{"focus":"Stomach Cancer - Surgery"},{"focus":"Thyroid Cancers"},{"focus":"Thyroid Cancers - Surgery "}],"appointments":[{"appointment":"Professor - Med Center Line,Surgery - General Surgery"},{"appointment":"Member,Cancer Center"}],"primaryAppointment":"Professor - Med Center Line,Surgery - General Surgery","imageUrl":"http://med.stanford.edu/profiles/viewImage?facultyId=3948&type=small&showNoImage","displayName":"Jeffrey Norton","firstName":"Jeffrey","href":"http://med.stanford.edu/profiles/cancer/researcher/Jeffrey_Norton","researchInterest":"Interleukin-12 is a Th1 cytokine.  It is important in the cell mediated immune response.  We are investigating its role as an anti-tumor cytokine to augment the immune response against cancer.  We are planning a human trial."},{"lastName":"Clarke","clinicalFocus":[{"focus":"Colorectal Cancer"},{"focus":"Oncology"},{"focus":"Oncology (Cancer)"}],"appointments":[{"appointment":"Professor,Medicine - Oncology"},{"appointment":"Member,Bio-X"},{"appointment":"Member,Cancer Center"}],"primaryAppointment":"Professor,Medicine - Oncology","imageUrl":"http://med.stanford.edu/profiles/viewImage?facultyId=7126&type=small&showNoImage","displayName":"Michael F. Clarke, M.D.","firstName":"Michael","href":"http://med.stanford.edu/profiles/cancer/researcher/Michael_Clarke","researchInterest":"Dr. Michael F. Clarke is the Associate Director of the Stanford Institute for Stem Cell and Regenerative Medicine.  In addition to his clinical duties in the division of Oncology, Dr. Clarke maintains a laboratory  focused on two areas of research: i) the control of self-renewal of normal stem cells and their malignant counterparts; and ii) the identification and characterization of cancer stem cells. A central issue in stem cell biology is to understand the mechanisms that regulate self-renewa"},{"lastName":"Felsher","clinicalFocus":[{"focus":"Hodgkin's Disease"},{"focus":"Hodgkin's Disease - Hematology"},{"focus":"Hodgkin's Disease - Medical Oncology"},{"focus":"Lymphoma "},{"focus":"Oncology"},{"focus":"Oncology (Cancer)"}],"appointments":[{"appointment":"Associate Professor,Medicine - Oncology"},{"appointment":"Associate Professor,Pathology"},{"appointment":"Member,Bio-X"},{"appointment":"Member,Cancer Center"}],"primaryAppointment":"Associate Professor,Medicine - Oncology","imageUrl":"http://med.stanford.edu/profiles/viewImage?facultyId=5931&type=small&showNoImage","displayName":"Dean W. Felsher","firstName":"Dean","href":"http://med.stanford.edu/profiles/cancer/researcher/Dean_Felsher","researchInterest":"My laboratory investigates how oncogenes initiate and sustain tumorigenesis. I have developed model systems whereby I can conditionally activate oncogenes in normal human and mouse cells in tissue culture or in specific tissues of transgenic mice. In particular using the tetracycline regulatory system, I have generated a conditional model system for MYC-induced tumors. I have shown that cancers caused by the conditional over-expression of the MYC proto-oncogene regress with its inactivation."}]}